spacing-40
spacing-0
Do you have patients with unresolved symptoms in your practice like Dave?
spacing-40
spacing-24

Consider the profile of this hypothetical patient below:

h3
text-heading-sage-light
bold
left
20px | 32px
19px | 24px
spacing-6
spacing-14
Occupation: Currently unemployed     Age: 36     BMI: 31
text-body
font-whitney
weight-whitney-default
size-large
16px | 19.2px
14px | 16.8px
spacing-24
spacing-25

Current SZ Presentation:

h3
text-heading-sage-light
bold
left
20px | 32px
19px | 24px
spacing-5
spacing-15
  • On an atypical antipsychotic initiated at last hospitalization
  • Unresolved symptoms: hallucinations, paranoid delusions, social withdrawal, and agitation
  • Caregiver expresses interest in changing oral atypical antipsychotic
  • Reluctance to go on an LAI
text-body
font-whitney
weight-whitney-default
size-large
16px | 1.2em
16px | 1.2em
bullet-marigold-triangle
spacing-15
spacing-15
BMI, body mass index; LAI, long-acting injectable.
text-body
font-whitney
weight-whitney-default
size-large
11px | 1.4em
11px | 1.4em
bullet-marigold-triangle
spacing-6
spacing-6
41
8
Have more questions?
true
Request a representative
true
md
spacing-40

Continue exploring REXULTI

h2
size-h3
text-heading-emerald
whitney-black
center
| 32px
23px | 24px
heading-with-inline-line
sm
spacing-60
45
pill
Learn about once-daily treatment with a target dose of 2-4 mg.
GET DOSING INFORMATION
sm
spacing-34
0
style
col-50
folder
Review safety considerations for REXULTI in the treatment of schizophrenia.
View Safety Profile
style
col-50

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.

spacing-24